IMR Press / CEOG / Special Issues / in_vitro_fertilization

In-Vitro Fertilization (IVF)

Submission deadline: 31 December 2024
Special Issue Editor
  • Michael H. Dahan, MD
    Michael Dahan is on faculty in the Department of Obstetrics and Gynecology at McGill University. He graduated from medical school at the State University of New York at Stonybrook in 1996, Residency in obstetrics and gynecology at Long Island College Hospital in 2000 and a fellowship in reproductive endocrinology and infertility at the University of California at San Diego in 2003. Dr. Dahan has authored over 200 peer-reviewed publications and 200 abstracts and has been awarded over $1.3 million in research grants. He is a past Chair of the Associate Committee of the Society for Reproductive Endocrinology and Infertility (SREI). He has been invited to present nationally and internationally over 140 times. He is listed in Who is Who of Medicine. The name Dahan’s syndrome has been applied to pituitary injury due to vasospasm, which he first described in the medical literature. When he is not working, he enjoys traveling and spending time with his wife and five children.
    Interests: assisted reproductive technology; obstetrics and gynecology
Special Issue Information

Dear Colleagues,

In-vitro fertilization has continuously gained in popularity since its first delivery in 1978. This is primarily due to women delaying childbirth later in life and the ease of availability of care in many nations. IVF has changed significantly over the years, starting with clomiphene for ovarian stimulation, followed by human menopausal gonadotropins then recombinant FSH and LH. Techniques have been developed to prevent ovarian hyperstimulation which was once common and has become rare. Preimplantation testing of the embryos can be done to prevent disease and may improve certain outcomes. Intracytoplasmic sperm injection has been used to overcome severe male factor infertility. We can freeze oocytes to prolong fertility later in life in cancer patients and in women without partners. Ingenuity in IVF continues with novel mechanisms to prevent ovulation being developed. We at Clinical and Experimental Obstetrics & Gynecology are developing an issue of our journal focused on novel IVF outcomes and the ingenuity in this field.

Assis. Prof. Michael H. Dahan

Guest Editor

agonist trigger
ovarian hyperstimulation syndrome
progestins to prevent
fertility preservation
oocyte freezing
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (5 Papers)
Back to top